$CLX

Clorox forecasts upbeat annual sales as demand improves

Reuters reports Clorox (Pine-Sol maker) forecast fiscal 2027 net sales growth of 13% to 14%, above analysts’ 12.8% estimate, and adjusted EPS of $5.70 to $6 versus $5.97 expected. Q4 sales fell 2% to $1.95B but beat $1.90B. Gross margin dropped to 41.3%. Clorox cited improving demand amid a challenging cost and value-seeking environment.

Original reporting
Published Aug 3, 2026, 8:24 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 8:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$CLX
Neutral
medium confidence
Mentioned
$CLX
Relevance
8/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$CLXNeutralMed
01

Why it matters

The guidance update is the key tradable input, with explicit 2027 net sales and adjusted EPS ranges and a reported gross margin decline that can drive revisions.

02

Market read

Investors get a fresh demand and guidance read for 2027, but with mixed earnings signals due to margin compression and an EPS range below consensus.

03

What to watch

Gross margin fell 520 bps to 41.3%, and the EPS guidance range is below consensus, so traders should weigh cost volatility and pricing/mix dynamics more heavily than top-line growth.

Relevance 8/10Novelty 7/10Timing: pre-market today guidance and quarterly results update

Background

Clorox is positioning around health and wellness categories and recently expanded via the GOJO Industries acquisition to broaden hygiene exposure.

Company-level read

Ticker impact

$CLXNeutralMedium confidence
Context

Clorox guided fiscal 2027 net sales up 13% to 14% and adjusted EPS $5.70 to $6, citing improving demand despite macro uncertainty.

Expected impact

Near-term bias depends on whether traders focus more on the sales beat and demand recovery versus the weaker EPS outlook and margin compression.

Evidence & confidence

The article provides explicit 2027 net sales and adjusted EPS guidance versus analyst estimates, plus a reported gross margin drop and a recent acquisition backdrop.

Market effects

Signals resilience in household cleaning and disinfectant demand, potentially supporting sentiment for consumer staples and health-and-hygiene brands.

Mentions international customer demand as a support factor, which may matter for global consumer-staples positioning.

Macro uncertainty is acknowledged, but the company’s demand improvement narrative may influence how investors price defensive consumer exposure globally.

Counterpoint

The sales outlook may be offset by margin deterioration and a value-seeking consumer, making the earnings miss a warning sign rather than a simple demand rebound.

Key entities

  • Clorox

    Forecasts fiscal 2027 net sales growth of 13% to 14% and adjusted EPS of $5.70 to $6, citing improving demand.

  • GOJO Industries

    Acquired by Clorox in April for $2.25 billion to expand health and hygiene reach.

  • Linda Rendle

    CEO who said the operating environment remains challenging with cost volatility and a value-seeking consumer.

Related articles

$CLXMed

The Clorox Company Q4 2026 Earnings Call Summary

Clorox held its Q4 2026 earnings call, citing value-seeking consumer behavior and inflation pressures. Management said most categories have recovered from a prior cyberattack, with Litter still lagging. It highlighted GOJO acquisition synergies, fiscal 2027 assumptions including Brent at $90/bbl, inflation over $200M, and free cash flow of 11% to 13% of sales.

$CLXMedAI 8/10

Clorox fiscal 2027 outlook: inflation and value shoppers weigh

Clorox forecast a difficult fiscal 2027, citing inflation and consumers shifting to value. The company expects net sales up 13% to 14% for fiscal 2027, with about 9.5 points from its April 2026 GOJO Industries acquisition. Adjusted EPS is projected at $5.70 to $6.00, GAAP diluted EPS $5.41 to $5.71. Q4 revenue fell 2% to $1.95B; adjusted EPS was $1.66.

$CLXMedAI 8/10

CLOROX CO /DE/ (CLX): Results of Operations and Financial Condition

CLOROX CO /DE/ (CLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991-pressreleasedatedaug.htm EX-99.1 Document Clorox Reports Q4 and FY26 Results, Provides FY27 Outlook Delivers Q4 results in line with expectations while advancing strategic investments OAKLAND, California, Aug. 3, 2026 — The Clorox Company (NYSE: CLX) today reporte

$CLXMedAI 9/10

Clorox Announces Leadership Transition as CEO Linda Rendle Prepares to Exit

The Wall Street Journal reported May 28 that Clorox CEO Linda Rendle will step down for health reasons after more than two decades. Clorox said it has started a comprehensive search for a new chief executive, while Rendle will remain in her role. In a blog post, Rendle said she was diagnosed with early-stage breast cancer, is now cancer-free, and cited ongoing treatment side effects.

$KMBLow

Kimberly-Clark vs. The Clorox: Which Consumer Goods Stock Is a Better Buy in 2026?

The article compares Kimberly-Clark (KMB) and The Clorox Company (CLX) as consumer staples for 2026. Kimberly-Clark reported FY2025 revenue near $16.4B (down from $16.8B) and net income about $2.0B; Clorox reported FY2025 revenue near $7.1B (flat) and net income about $810M. It cites higher customer concentration for both (Walmart ~16% for KMB, ~27% for Clorox) and notes KMB is selling tissue operations to Suzano and has a potential $48B merger with Kenvue, while Clorox is recovering from a 2023